ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

belvarafenib

Also written as “Belvarafenib”, “HM95573, cobimetinib” and “HM95573, cetuximab”.

Its studies are mostly in Melanoma · Neoplasm Metastasis · Neoplasms, led by 2 companies.

Drug pageBelvarafenib: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Feb 27, 20266 company-led studies, 4 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hanmi Pharmaceutical42 open or runningphase 2since Feb 27, 2026Jan 15, 2015Sep 2029phase 2 · NCT07449754
Hoffmann-La Rocheits history only22 open or runningphase 2since Oct 11, 2020Oct 11, 2020Dec 31, 2026phase 1 · NCT04835805

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hanmi Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jan 15, 2015First study: phase 1 study in NeoplasmsFirst studyNCT02405065 · 72 enrolled · Korea, Republic of
  2. Mar 20, 2017Phase 1 study in Solid TumorNCT03118817 · 65 enrolled · Korea, Republic of
  3. Aug 7, 2017Phase 1 study in Neoplasm MetastasisNCT03284502 · 148 enrolled · Korea, Republic of
  4. Dec 9, 2017Named belvarafenibINNProposed as its International Nonproprietary Name in WHO's List 118 · before, HM95573
  5. Feb 27, 2026Phase 2 study in MelanomaPhase 2 reachedNCT07449754 · 45 planned · South Korea

Ahead

  1. Sep 2029Primary completion: phase 2 study in MelanomaNCT07449754

TargetBeta

“RAF serine/threonine protein kinase inhibitor”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
tovorafenibruleday-one-biopharmaceuticals-incphase 38

Studies

All 4 Hanmi Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07449754Melanoma · South Korea2RecruitingSep 202945
NCT03284502Neoplasm Metastasis · Korea, Republic of1Active, not recruitingSep 30, 2024148
NCT03118817Solid Tumor · Korea, Republic of1CompletedFeb 4, 202065
NCT02405065Neoplasms · Korea, Republic of1CompletedJan 18, 201772

How it is read

Names in the registry

  • “Belvarafenib”, 3 entries
  • “HM95573, cobimetinib”, 2 entries
  • “HM95573, cetuximab”, 2 entries
  • “HM95573”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.